• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

透明质酸-壳聚糖纳米粒药物传递系统中 0.005%拉坦前列素滴眼液对兔眼内压的降低作用。

Intraocular Pressure Reduction Effect of 0.005% Latanoprost Eye Drops in a Hyaluronic Acid-Chitosan Nanoparticle Drug Delivery System in Albino Rabbits.

机构信息

The Graduate School, University of Santo Tomas, Manila, Philippines.

School of Pharmacy, Centro Escolar University, Manila, Philippines.

出版信息

Transl Vis Sci Technol. 2021 Apr 1;10(4):2. doi: 10.1167/tvst.10.4.2.

DOI:10.1167/tvst.10.4.2
PMID:34003979
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8024779/
Abstract

PURPOSE

The purpose of this study was to evaluate the intraocular pressure (IOP) reduction efficiency of hyaluronic acid-chitosan-latanoprost link nanoparticle (HA-CS-latanoprost link NP) formulated eye drops.

METHODS

The IOP reduction study was performed in 24 normotensive albino rabbits. The test animals were randomized and grouped accordingly to treatment namely, HA-CS-latanoprost link NP, plain latanoprost, and the commercially available Xalatan eye drop, all were formulated with 0.005% latanoprost. The 9 days of the experiment were divided into baseline period (days 1-2), treatment period (days 3-6), and recovery period (days 7-9). A wireless noncontact tonometer was used to measure IOP at a time interval of 2 hours for 12 hours per day with 5 readings each.

RESULTS

The highest mean daily IOP reduction during the treatment period was 24% for plain latanoprost, 23% for Xalatan, and 29% for HA-CS-latanoprost link NP. The maximum reduction in IOP for plain latanoprost and Xalatan all occurred at the sixth hour with the peak effects of 4.85 mm Hg (37%) and 4.8 mm Hg (36%), respectively. Although HA-CS-latanoprost link NP had peak effects of 5.75 mm Hg (43%) at the sixth hour and 5.22 mm Hg (39%) at the eighth hour. Daily mean IOP measurements of each treatment group showed that HA-CS-latanoprost link NP has a greater IOP reduction effect compared with the other two treatments (P < 0.001).

CONCLUSIONS

The results showed that the formulation of latanoprost with CS and HA is more effective in reducing the IOP than by drug alone.

TRANSLATIONAL RELEVANCE

The results provide evidence from animal experiment that HA-CS-latanoprost link NP formulation could improve and sustain drug concentration in the anterior segment of the eye. The improved reduction in IOP with that HA-CS-latanoprost link NP formulation can serve as a basis that latanoprost eye drops can be formulated with decreased concentration of benzalkonium HCl, an irritant preservative and penetration enhancer.

摘要

目的

本研究旨在评估透明质酸-壳聚糖-拉坦前列素链接纳米颗粒（HA-CS-latanoprost link NP）滴眼剂的降眼压（IOP）效率。

方法

在 24 只正常眼压的白化兔中进行了眼压降低研究。将实验动物随机分组，分别接受以下治疗：HA-CS-latanoprost link NP、普通拉坦前列素和市售 Xalatan 滴眼剂，均含有 0.005%拉坦前列素。实验分为 9 天，包括基线期（第 1-2 天）、治疗期（第 3-6 天）和恢复期（第 7-9 天）。使用无线非接触眼压计在每天 12 小时内每隔 2 小时测量 IOP，每次测量 5 次读数。

结果

在治疗期间，普通拉坦前列素、Xalatan 和 HA-CS-latanoprost link NP 的平均每日 IOP 降低率最高，分别为 24%、23%和 29%。普通拉坦前列素和 Xalatan 的最大 IOP 降低均发生在第六小时，峰值效应分别为 4.85 毫米汞柱（37%）和 4.8 毫米汞柱（36%）。虽然 HA-CS-latanoprost link NP 在第六小时的峰值效应为 5.75 毫米汞柱（43%），在第八小时的峰值效应为 5.22 毫米汞柱（39%）。每个治疗组的每日平均 IOP 测量值显示，与其他两种治疗方法相比，HA-CS-latanoprost link NP 具有更大的 IOP 降低效果（P<0.001）。

结论

结果表明，CS 和 HA 与拉坦前列素联合使用比单独使用药物更能有效降低眼压。

翻译

陈颖怡

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a574/8024779/7bf281315df1/tvst-10-4-2-f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a574/8024779/074700d32a3c/tvst-10-4-2-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a574/8024779/6d7babac0c0a/tvst-10-4-2-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a574/8024779/a16212f7fd2c/tvst-10-4-2-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a574/8024779/358f0e194266/tvst-10-4-2-f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a574/8024779/64e6c7a6fca9/tvst-10-4-2-f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a574/8024779/7bf281315df1/tvst-10-4-2-f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a574/8024779/074700d32a3c/tvst-10-4-2-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a574/8024779/6d7babac0c0a/tvst-10-4-2-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a574/8024779/a16212f7fd2c/tvst-10-4-2-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a574/8024779/358f0e194266/tvst-10-4-2-f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a574/8024779/64e6c7a6fca9/tvst-10-4-2-f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a574/8024779/7bf281315df1/tvst-10-4-2-f006.jpg

相似文献

1
Intraocular Pressure Reduction Effect of 0.005% Latanoprost Eye Drops in a Hyaluronic Acid-Chitosan Nanoparticle Drug Delivery System in Albino Rabbits.透明质酸-壳聚糖纳米粒药物传递系统中 0.005%拉坦前列素滴眼液对兔眼内压的降低作用。
Transl Vis Sci Technol. 2021 Apr 1;10(4):2. doi: 10.1167/tvst.10.4.2.
2
A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.一种无防腐剂拉坦前列素阳离子乳剂（Catioprost）和一种含苯扎氯铵防腐剂的拉坦前列素溶液在动物模型中的比较研究。
J Ocul Pharmacol Ther. 2012 Oct;28(5):515-23. doi: 10.1089/jop.2011.0245. Epub 2012 Jun 6.
3
Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.马来酸噻吗洛尔 0.5%/多佐胺 2%（适利达）固定组合制剂对升高的眼压患者单药治疗的降眼压附加作用：一项前瞻性、4 周、开放标签、随机、对照临床试验。
J Glaucoma. 2010 Jun-Jul;19(5):331-5. doi: 10.1097/IJG.0b013e3181b4cab4.
4
A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes.拉坦前列素（适利达）与异丙基乌诺前列酮（瑞奇）在正常和青光眼猴眼中的对比研究。
Jpn J Ophthalmol. 1998 Mar-Apr;42(2):95-100. doi: 10.1016/s0021-5155(97)00128-7.
5
Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes.在青光眼猴眼中比马前列素或曲伏前列素与拉坦前列素的相加作用。
Arch Ophthalmol. 2004 Sep;122(9):1342-7. doi: 10.1001/archopht.122.9.1342.
6
Effect of different dose schedules of latanoprost on intraocular pressure and pupil size in the glaucomatous Beagle.不同给药方案的拉坦前列素对青光眼比格犬眼压和瞳孔大小的影响。
Vet Ophthalmol. 2001 Dec;4(4):283-8. doi: 10.1046/j.1463-5216.2001.00201.x.
7
Pharmacokinetics and Pharmacology of Latanoprost 0.005% without Benzalkonium Chloride Vs Latanoprost 0.005% with Benzalkonium Chloride in New Zealand White Rabbits and Beagles.拉坦前列素 0.005%无苯扎氯铵与拉坦前列素 0.005%含苯扎氯铵在新西兰白兔和比格犬中的药代动力学和药效学比较。
Curr Eye Res. 2021 Jul;46(7):1031-1037. doi: 10.1080/02713683.2020.1855660. Epub 2021 Mar 15.
8
Latanoprost 0.005% test formulation is as effective as Xalatan® in patients with ocular hypertension and primary open-angle glaucoma.拉坦前列素0.005%测试制剂在高眼压症和原发性开角型青光眼患者中与适利达®效果相当。
Eur J Ophthalmol. 2012 Jan-Feb;22(1):19-27. doi: 10.5301/ejo.5000041.
9
Peak pressures: crossover study of timolol and latanoprost.峰值眼压：噻吗洛尔与拉坦前列素的交叉研究。
Eur J Ophthalmol. 2003 Jul;13(6):546-52. doi: 10.1177/112067210301300607.
10
Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation.前列腺素类似物与小鼠眼压：考虑24小时眼压变化，探讨他氟前列素、拉坦前列素、曲伏前列素和乌诺前列酮的作用
Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2006-11. doi: 10.1167/iovs.04-1527.

引用本文的文献

1
An Update on Novel Drug Delivery Systems for the Management of Glaucoma.用于青光眼治疗的新型药物递送系统的最新进展
Pharmaceutics. 2025 Aug 21;17(8):1087. doi: 10.3390/pharmaceutics17081087.
2
Topical Ocular Drug Delivery: The Impact of Permeation Enhancers.眼部局部给药：渗透促进剂的影响
Pharmaceutics. 2025 Mar 31;17(4):447. doi: 10.3390/pharmaceutics17040447.
3
How to Fabricate Hyaluronic Acid for Ocular Drug Delivery.如何制备用于眼部药物递送的透明质酸。

本文引用的文献

1
Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments.用于眼部给药制剂的壳聚糖及其衍生物：最新进展与发展
Polymers (Basel). 2020 Jul 8;12(7):1519. doi: 10.3390/polym12071519.
2
Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment.载有曲伏前列素的自组装 DNA 纳米颗粒用于青光眼治疗。
Nanomedicine. 2020 Oct;29:102260. doi: 10.1016/j.nano.2020.102260. Epub 2020 Jul 3.
3
Topical delivery of acetazolamide by encapsulating in mucoadhesive nanoparticles.通过包裹在粘膜粘附纳米颗粒中进行乙酰唑胺的局部给药。
Pharmaceutics. 2024 Dec 16;16(12):1604. doi: 10.3390/pharmaceutics16121604.
4
Nanomedicine in glaucoma treatment; Current challenges and future perspectives.青光眼治疗中的纳米医学：当前挑战与未来展望。
Mater Today Bio. 2024 Sep 4;28:101229. doi: 10.1016/j.mtbio.2024.101229. eCollection 2024 Oct.
5
Research progress of nano delivery systems for intraocular pressure lowering drugs.降眼压药物纳米递送系统的研究进展
Heliyon. 2024 Jun 12;10(12):e32602. doi: 10.1016/j.heliyon.2024.e32602. eCollection 2024 Jun 30.
6
Therapeutic Aqueous Humor Concentrations of Latanoprost Attained in Rats by Administration in a Very-High-Molecular-Weight Hyaluronic Acid Eye Drop.通过超高分子量透明质酸滴眼液给药在大鼠中达到的拉坦前列素治疗性房水浓度。
Pharmaceutics. 2024 Apr 9;16(4):523. doi: 10.3390/pharmaceutics16040523.
7
Sustained release of brimonidine from polydimethylsiloxane-coating silicone rubber implant to reduce intraocular pressure in glaucoma.溴莫尼定从聚二甲基硅氧烷涂层硅橡胶植入物中的持续释放以降低青光眼患者的眼压。
Regen Biomater. 2023 Apr 24;10:rbad041. doi: 10.1093/rb/rbad041. eCollection 2023.
8
Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma.基于壳聚糖的纳米药物在青光眼眼部应用中的最新进展
Pharmaceutics. 2023 Feb 17;15(2):681. doi: 10.3390/pharmaceutics15020681.
9
Aqueous Prostaglandin Eye Drop Formulations.水性前列腺素滴眼液制剂
Pharmaceutics. 2022 Oct 9;14(10):2142. doi: 10.3390/pharmaceutics14102142.
10
Hyaluronic Acid: Its Versatile Use in Ocular Drug Delivery with a Specific Focus on Hyaluronic Acid-Based Polyelectrolyte Complexes.透明质酸：其在眼部药物递送中的广泛应用，特别关注基于透明质酸的聚电解质复合物。
Pharmaceutics. 2022 Jul 15;14(7):1479. doi: 10.3390/pharmaceutics14071479.
Asian J Pharm Sci. 2017 Nov;12(6):550-557. doi: 10.1016/j.ajps.2017.04.005. Epub 2017 May 16.
4
Penetration Enhancers in Ocular Drug Delivery.眼部药物递送中的渗透促进剂
Pharmaceutics. 2019 Jul 9;11(7):321. doi: 10.3390/pharmaceutics11070321.
5
Concepts for Developing Physical Gels of Chitosan and of Chitosan Derivatives.壳聚糖及其衍生物物理凝胶的开发概念
Gels. 2018 Aug 9;4(3):67. doi: 10.3390/gels4030067.
6
Normal tension glaucoma: review of current understanding and mechanisms of the pathogenesis.正常眼压性青光眼：当前认识和发病机制的研究进展。
Eye (Lond). 2018 May;32(5):924-930. doi: 10.1038/s41433-018-0042-2. Epub 2018 Feb 19.
7
Chitosan Nanoparticles as a Mucoadhesive Drug Delivery System for Ocular Administration.壳聚糖纳米粒作为眼部给药的黏膜粘附性药物传递系统。
Mar Drugs. 2017 Dec 1;15(12):370. doi: 10.3390/md15120370.
8
An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery.壳聚糖纳米颗粒概述及其在非肠道给药中的应用
Pharmaceutics. 2017 Nov 20;9(4):53. doi: 10.3390/pharmaceutics9040053.
9
Nanoparticles for drug delivery to the anterior segment of the eye.用于眼部前段递药的纳米粒。
Adv Drug Deliv Rev. 2017 Dec 1;122:31-64. doi: 10.1016/j.addr.2017.04.001. Epub 2017 Apr 6.
10
Hyaluronic Acid-Chitosan Nanoparticles to Deliver Gd-DTPA for MR Cancer Imaging.用于磁共振癌症成像的载钆喷酸葡胺的透明质酸-壳聚糖纳米颗粒
Nanomaterials (Basel). 2015 Aug 20;5(3):1379-1396. doi: 10.3390/nano5031379.